Apomorphine vs. ropinirole: What the newer canine emesis data show
CURRENT BRIEF VERSION: Veterinary teams weighing apomorphine against ropinirole for canine emesis are now working with a more nuanced evidence base than they had a few years ago. Ropinirole ophthalmic solution, marketed as Clevor, was FDA-approved in June 2020 as the first approved drug to induce vomiting in dogs, with pivotal data showing 95% of treated dogs vomited within 30 minutes and 14% needed a second dose. More recent comparative research, including a prospective randomized 2025 emergency-hospital study of 132 client-owned dogs with suspected toxin or foreign-body ingestion, has complicated the picture: a 2023 study reported similar overall efficacy between ropinirole and apomorphine for removing gastric material, while newer 2024 and 2025 studies found apomorphine produced faster emesis, higher first-dose success, and less need for rescue therapy in emergency settings. (fda.gov)
Why it matters: For veterinary professionals, this is less about naming a universal winner and more about matching the emetic to the case. Ropinirole offers an on-label, ophthalmic option that avoids injection and may fit some workflows well, but its label and FDA summary also highlight ocular adverse effects, including conjunctival hyperemia, third-eyelid protrusion, blepharospasm, and rare corneal ulceration, along with lethargy, tachycardia, and prolonged vomiting. Apomorphine remains widely used off-label and is often viewed as the faster choice when rapid decontamination matters most. And when vomiting becomes prolonged after emesis induction, clinics are also paying attention to antiemetic logistics: metoclopramide has been cited for ropinirole-associated protracted vomiting, while maropitant remains a common rescue option, with a newly approved injectable bioequivalent, Emeprev, expected to reach distributors in early 2026. (animaldrugsatfda.fda.gov)
What to watch: Expect clinicians to keep focusing on speed, reversibility, adverse-event management, rescue antiemetic availability, and case selection as more head-to-head data emerge and protocols evolve. (pubmed.ncbi.nlm.nih.gov)